Literature DB >> 11901178

Serial killer: angiotensin drives cardiac hypertrophy via TGF-beta1.

Michael D Schneider1.   

Abstract

Entities:  

Keywords:  Non-programmatic

Mesh：

Substances：

Year:  2002        PMID： 11901178      PMCID： PMC150918          DOI： 10.1172/JCI15292

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  14 in total

1.  Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.

Authors:  T Senbonmatsu; S Ichihara; E Price; F A Gaffney; T Inagami
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts.

Authors:  M O Gray; C S Long; J E Kalinyak; H T Li; J S Karliner
Journal:  Cardiovasc Res       Date:  1998-11       Impact factor: 10.787

4.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

5.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

Authors:  N Prenzel; E Zwick; H Daub; M Leserer; R Abraham; C Wallasch; A Ullrich
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

6.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice.

Authors:  D Zhang; V Gaussin; G E Taffet; N S Belaguli; M Yamada; R J Schwartz; L H Michael; P A Overbeek; M D Schneider
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

7.  Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2.

Authors:  C Pellieux; A Foletti; G Peduto; J F Aubert; J Nussberger; F Beermann; H R Brunner; T Pedrazzini
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells.

Authors:  Y Uchiyama-Tanaka; H Matsubara; Y Nozawa; S Murasawa; Y Mori; A Kosaki; K Maruyama; H Masaki; Y Shibasaki; S Fujiyama; A Nose; O Iba; T Hasagawa; E Tateishi; S Higashiyama; T Iwasaka
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

9.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Authors:  Masanori Asakura; Masafumi Kitakaze; Seiji Takashima; Yulin Liao; Fuminobu Ishikura; Tsuyoshi Yoshinaka; Hiroshi Ohmoto; Koichi Node; Kohichiro Yoshino; Hiroshi Ishiguro; Hiroshi Asanuma; Shoji Sanada; Yasushi Matsumura; Hiroshi Takeda; Shintaro Beppu; Michihiko Tada; Masatsugu Hori; Shigeki Higashiyama
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

Review 10.  Genetic dissection of cardiac growth control pathways.

Authors:  W R MacLellan; M D Schneider
Journal:  Annu Rev Physiol       Date:  2000       Impact factor: 19.318
View more
  6 in total

Review 1.  Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research.

Authors:  Vikrant Rai; Poonam Sharma; Swati Agrawal; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-10-20       Impact factor: 3.396

2.  TGFbeta neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.

Authors:  Susan M Faust; Guanyi Lu; Sherri C Wood; D Keith Bishop
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

3.  MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis.

Authors:  Varun Nagpal; Rahul Rai; Aaron T Place; Sheila B Murphy; Suresh K Verma; Asish K Ghosh; Douglas E Vaughan
Journal:  Circulation       Date:  2015-11-19       Impact factor: 29.690

4.  Protective and Therapeutic Effects of Chinese Medicine Formula Jiajian Yunvjian on Experimental Cardiac Remodeling after Myocardial Infarction Induced by Coronary Artery Ligation.

Authors:  Jun Du; Wei-Liang Gu; Chang-Xun Chen; Ying Wang; Jian Lv
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-22       Impact factor: 2.629

5.  MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis.

Authors:  Li Li; Kelsey R Bounds; Piyali Chatterjee; Sudhiranjan Gupta
Journal:  J Am Heart Assoc       Date:  2017-11-07       Impact factor: 5.501

6.  Sirtuin 3 is essential for hypertension-induced cardiac fibrosis via mediating pericyte transition.

Authors:  Han Su; Heng Zeng; Bo Liu; Jian-Xiong Chen
Journal:  J Cell Mol Med       Date:  2020-05-28       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.